273 related articles for article (PubMed ID: 21098043)
1. Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.
Levitt ES; Purington LC; Traynor JR
Mol Pharmacol; 2011 Mar; 79(3):461-71. PubMed ID: 21098043
[TBL] [Abstract][Full Text] [Related]
2. Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.
Alt A; Clark MJ; Woods JH; Traynor JR
Br J Pharmacol; 2002 Jan; 135(1):217-25. PubMed ID: 11786497
[TBL] [Abstract][Full Text] [Related]
3. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors.
Shapira M; Vogel Z; Sarne Y
Cell Mol Neurobiol; 2000 Jun; 20(3):291-304. PubMed ID: 10789829
[TBL] [Abstract][Full Text] [Related]
4. Mediation of adenylyl cyclase sensitization by PTX-insensitive GalphaoA, Galphai1, Galphai2 or Galphai3.
Clark MJ; Traynor JR
J Neurochem; 2006 Dec; 99(6):1494-504. PubMed ID: 17230639
[TBL] [Abstract][Full Text] [Related]
5. Opioid-induced down-regulation of RGS4: role of ubiquitination and implications for receptor cross-talk.
Wang Q; Traynor JR
J Biol Chem; 2011 Mar; 286(10):7854-7864. PubMed ID: 21209077
[TBL] [Abstract][Full Text] [Related]
6. Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain.
Carter BD; Medzihradsky F
Proc Natl Acad Sci U S A; 1993 May; 90(9):4062-6. PubMed ID: 8097884
[TBL] [Abstract][Full Text] [Related]
7. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
8. Modulation of μ-opioid receptor signaling by RGS19 in SH-SY5Y cells.
Wang Q; Traynor JR
Mol Pharmacol; 2013 Feb; 83(2):512-20. PubMed ID: 23197645
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
10. Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.
Talbot JN; Roman DL; Clark MJ; Roof RA; Tesmer JJ; Neubig RR; Traynor JR
J Neurochem; 2010 Feb; 112(4):1026-34. PubMed ID: 20002516
[TBL] [Abstract][Full Text] [Related]
11. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
[TBL] [Abstract][Full Text] [Related]
12. Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.
Clark MJ; Harrison C; Zhong H; Neubig RR; Traynor JR
J Biol Chem; 2003 Mar; 278(11):9418-25. PubMed ID: 12524446
[TBL] [Abstract][Full Text] [Related]
13. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Clark MJ; Traynor JR
J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
[TBL] [Abstract][Full Text] [Related]
14. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
Breivogel CS; Selley DE; Childers SR
J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase.
Levitt ES; Clark MJ; Jenkins PM; Martens JR; Traynor JR
J Biol Chem; 2009 Aug; 284(33):22108-22122. PubMed ID: 19520863
[TBL] [Abstract][Full Text] [Related]
16. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
Szücs M; Boda K; Gintzler AR
J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951
[TBL] [Abstract][Full Text] [Related]
17. The delta-opioid receptor is sufficient, but not necessary, for spinal opioid-adrenergic analgesic synergy.
Chabot-Doré AJ; Millecamps M; Stone LS
J Pharmacol Exp Ther; 2013 Dec; 347(3):773-80. PubMed ID: 24039246
[TBL] [Abstract][Full Text] [Related]
18. ABIN-1 Negatively Regulates
Zhou P; Jiang J; Yan H; Li Y; Zhao J; Wang X; Su R; Gong Z
Mol Pharmacol; 2018 Feb; 93(2):36-48. PubMed ID: 29237725
[TBL] [Abstract][Full Text] [Related]
19. Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine D1 receptors in delta opioid receptor-mediated signal transduction.
Unterwald EM; Cuntapay M
Neuropharmacology; 2000 Jan; 39(3):372-81. PubMed ID: 10698003
[TBL] [Abstract][Full Text] [Related]
20. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
Divin MF; Bradbury FA; Carroll FI; Traynor JR
Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
